Aspire Biopharma Holdings (ASBP) Net Income towards Common Stockholders (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$3.2 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 79.78% year-over-year to -$3.2 million in Q1 2026; TTM through Mar 2026 was -$13.9 million, a 19.73% increase from a year earlier, with the FY2025 full-year figure at -$19.3 million, down 54.26% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$3.2 million, up from -$8.1 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for ASBP reached as high as $1.5 million in Q2 2023 and fell as low as -$15.9 million in Q1 2025.
• Historically, Net Income towards Common Stockholders has averaged -$1.9 million across 5 years, with a median of -$162636.0 in 2023.
• Across the five-year window, Net Income towards Common Stockholders slumped 11635.1% in 2022 and jumped 5970.52% in 2023, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$88600.0 in 2022, then decreased by 23.03% to -$109003.0 in 2023, then sank by 446.44% to -$595639.0 in 2024, then plunged by 1257.0% to -$8.1 million in 2025, then soared by 60.13% to -$3.2 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$3.2 million in Q1 2026, -$8.1 million in Q4 2025, and -$2.6 million in Q3 2025.